-
AACR CEO Margaret Foti, PhD, MD (hc): Thank you for an outstanding AACR Annual Meeting 2025
An incredible scientific program at the AACR Annual Meeting 2025 showcased the amazing leaps being made across the continuum of cancer research and demonstrated the shared commitment to driving progress against cancer.
-
Closing Plenary Session showcases meeting’s key takeaways across the continuum of cancer research
Annual Meeting Program Chairs Matthew G. Vander Heiden, MD, PhD, and AACR President Lillian L. Siu, MD, FAACR, introduced three speakers who summarized the major themes, discoveries, and impact of findings reported throughout the meeting.
-
New Drugs on the Horizon sessions provide first look at 12 new therapeutics
Three sessions showcased first disclosures of agents in or nearing early-stage clinical trials, including a new wave of precision KRAS inhibitors and therapies aimed at reprogramming the tumor-immune microenvironment.
More news
-
Irving Weinstein Foundation award lecturer highlights potential of GLPs in cancer care
Daniel J. Drucker, MD, was honored with the 2025 AACR-Irving Weinstein Foundation Distinguished Lectureship for his contributions to endocrinology, physiology and metabolism, and the characterization of hormone functionality.
-
Margaret Foti Award recipient reflects on accomplishments in both academia and industry
William N. Hait, MD, PhD, FAACR, was recognized with the 2025 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research because of his extensive contributions to cancer pharmacology, drug discovery, and precision medicine.
-
Third Plenary Session showcases exciting technologies driving innovation
Muhammad Shaalan Beg, MD, MBA, explained on Monday how clinical investigators can use new technologies to decentralize clinical trials, conducting portions of the trial at sites distanced from the principal investigator.
Meet the 2025 NextGen Stars
